139 related articles for article (PubMed ID: 38275480)
21. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
[TBL] [Abstract][Full Text] [Related]
22. The lung cancers: staging and response, CT,
Owens C; Hindocha S; Lee R; Millard T; Sharma B
Br J Radiol; 2023 Aug; 96(1148):20220339. PubMed ID: 37097296
[TBL] [Abstract][Full Text] [Related]
23. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
[TBL] [Abstract][Full Text] [Related]
24. PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment.
Iravani A; Turgeon GA; Akhurst T; Callahan JW; Bressel M; Everitt SJ; Siva S; Hofman MS; Hicks RJ; Ball DL; Mac Manus MP
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1869-1877. PubMed ID: 31190177
[TBL] [Abstract][Full Text] [Related]
25. Abnormal brain glucose metabolism patterns in patients with advanced non-small-cell lung cancer after chemotherapy：A retrospective PET study.
Yu J; Cao X; Zhou R; Chen Q; Wang Y
Brain Res Bull; 2023 Oct; 202():110751. PubMed ID: 37625525
[TBL] [Abstract][Full Text] [Related]
26. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL;
Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429
[TBL] [Abstract][Full Text] [Related]
27. Staging
Voskuilen CS; van Gennep EJ; Einerhand SMH; Vegt E; Donswijk ML; Bruining A; van der Poel HG; Horenblas S; Hendricksen K; van Rhijn BWG; Mertens LS
Eur Urol Oncol; 2022 Jun; 5(3):366-369. PubMed ID: 33583752
[TBL] [Abstract][Full Text] [Related]
28. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection.
Lee JW; Na JO; Kang DY; Lee SY; Lee SM
Clin Lung Cancer; 2017 Mar; 18(2):198-206. PubMed ID: 27495385
[TBL] [Abstract][Full Text] [Related]
30. Post-treatment
Jung AR; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
Oral Oncol; 2020 Aug; 107():104750. PubMed ID: 32361565
[TBL] [Abstract][Full Text] [Related]
31. Consistency and prognostic value of preoperative staging and postoperative pathological staging using
Kajiyama A; Ito K; Watanabe H; Mizumura S; Watanabe SI; Yatabe Y; Gomi T; Kusumoto M
Ann Nucl Med; 2022 Dec; 36(12):1059-1072. PubMed ID: 36264439
[TBL] [Abstract][Full Text] [Related]
32. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
[TBL] [Abstract][Full Text] [Related]
33. What
Turgeon GA; Iravani A; Akhurst T; Beaulieu A; Callahan JW; Bressel M; Cole AJ; Everitt SJ; Siva S; Hicks RJ; Ball DL; Mac Manus MP
J Nucl Med; 2019 Mar; 60(3):328-334. PubMed ID: 30030343
[TBL] [Abstract][Full Text] [Related]
34. An [
Meng N; Feng P; Yu X; Wu Y; Fu F; Li Z; Luo Y; Tan H; Yuan J; Yang Y; Wang Z; Wang M
Eur Radiol; 2024 Jan; 34(1):318-329. PubMed ID: 37530809
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
36. Stage migration in planning PET/CT scans in patients due to receive radiotherapy for non-small-cell lung cancer.
Geiger GA; Kim MB; Xanthopoulos EP; Pryma DA; Grover S; Plastaras JP; Langer CJ; Simone CB; Rengan R
Clin Lung Cancer; 2014 Jan; 15(1):79-85. PubMed ID: 24238934
[TBL] [Abstract][Full Text] [Related]
37. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.
Kalff V; Hicks RJ; MacManus MP; Binns DS; McKenzie AF; Ware RE; Hogg A; Ball DL
J Clin Oncol; 2001 Jan; 19(1):111-8. PubMed ID: 11134203
[TBL] [Abstract][Full Text] [Related]
38. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
Li M; Wu N; Liu Y; Zheng R; Liang Y; Zhang W; Zhao P
Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
[TBL] [Abstract][Full Text] [Related]
39.
Kim SA; Roh JL; Kim JS; Lee JH; Lee SH; Choi SH; Nam SY; Kim SY
Eur J Cancer; 2017 Feb; 72():62-70. PubMed ID: 28027517
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic performance of FDG PET/CT for surveillance in asymptomatic gastric cancer patients after curative surgical resection.
Lee JW; Lee SM; Son MW; Lee MS
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):881-888. PubMed ID: 26611426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
